Search Medical Condition
Please enter condition
Please choose location from dropdown

Brno, Czech Republic Clinical Trials

A listing of Brno, Czech Republic clinical trials actively recruiting patients volunteers.

RESULTS

Found (207) clinical trials

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

A multi-regional clinical trial with participating sites planned in the following countries pending approval from the applicable oversight authorities: Argentina Brazil Bulgaria Canada Colombia Czech Republic Denmark France Germany Hungary India Israel Japan Mexico Netherlands Poland Romania Russian Federation Slovakia South Africa Spain Ukraine United Kingdom United States

Phase

0.0 miles

Learn More »

Strategic MAnagement to Optimize Response To Cardiac Resynchronization Therapy Registry

To learn in a general Cardiac Resynchronization Therapy Defibrillators (CRT-D) population, which optimization techniques are used and how effective they are. It will compare 12-month response rates among different optimization methods and characterize which selected subject subgroups achieve better response than others. A subset of SMART Registry subjects will contribute ...

Phase N/A

0.0 miles

Learn More »

A Study of Melflufen-dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

This is a randomized, controlled, open-label, Phase 3 multicenter study which will enroll patients with RRMM following 2-4 lines of prior therapy and who are refractory to lenalidomide in the last line of therapy as demonstrated by disease progression on or within 60 days of completion of the last dose ...

Phase

0.0 miles

Learn More »

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

The main objective of this trial is the safety and tolerability of 4 multiple rising oral doses of BI 685509 over 28 days in male and female patients with Diabetic Nephropathy (DN) as adjunctive to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB). Another objective is the change ...

Phase

0.0 miles

Learn More »

Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma

Study E7080-G000-218 is a Randomized, open-label (formerly Double-blind), Phase 2 Trial conducted to assess whether a starting dose of lenvatinib 14 milligrams (mg) in combination with everolimus 5 mg once daily (QD) will provide comparable efficacy (based on objective response rate [ORR] at 24 weeks [ORR24W]) with an improved safety ...

Phase

0.0 miles

Learn More »

Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone

This is a multicenter, Phase 3, randomized, open-label study comparing daratumumab, pomalidomide and low-dose dexamethasone (DaraPomDex) with pomalidomide and low-dose dexamethasone (PomDex) in subjects with relapsed or refractory Multiple Myeloma who have received at least 1 prior treatment regimen with both lenalidomide and a proteasome inhibitor and have demonstrated disease ...

Phase

0.0 miles

Learn More »

Study of Safety Tolerability Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions.

The purpose of this study is to assess the efficacy, safety and tolerability of multiple intra-articular (i.a.) injections of LNA043 over 4-weeks, in regenerating the articular surface in patients with cartilage lesions of the knee.

Phase

0.0 miles

Learn More »

Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

Duration of the study, per patient, will include eligibility period (screening period) of up to 4 weeks (28 days), treatment period (at least 1 cycle [28 days] of study treatment), and end of treatment (EOT) visit after the last study treatment administration (i.e. at least 30 days post last treatment ...

Phase

0.0 miles

Learn More »

Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

This is a multicenter, open-label study comprised of pretreatment, treatment (core study), and extension phases that is designed to evaluate the PK of an oral suspension of perampanel (target dose of 12 milligrams per day [mg /day] for non-enzyme-inducing antiepileptic drug [non-EIAED] or 16 mg/day for EIAED) when given as ...

Phase

0.0 miles

Learn More »